Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 56.61

-0.6%

Nov 6 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who wrote (1145)	5/30/2000 11:09:00 AM
From: JOEBT1	Read Replies (2) of 52153

Miljenko-I respect and have benefited from your posts. I want to call your attention to Immunogen (IMGN) which has made 4 deals for its "tumor-activated pro drug" technology with Smith Kline Beecham, Genentech(2 deals),and British Biotech. These deals would be worth 100 to 200 Million in milestone payments and upfront money plus significant royalties. They have received about 20 million in upfront/ milestone payments thus far. They anticipate additional deals this year. Their TAP technology consists of humanized monoclonal antibodies conjugated with a cytotoxic drug that target the cancer and releases the toxic drug to kill cancer cells. They have demonstrated total eradication of colon, pancreatic,small cell lung and prostate cancers in mice. In their Phase 1/2 trial with SKB they are on their 5th dose to patients (colon and pancreatic cancer)-no toxicity or immunogenecity so far. They only redose patients if the cancer is not progressing. Their website was updated over the weekend. It's informative and positive. Her is the website. imgn.com If you check it out I'd appreciate any comments you might have. I'm heavily long and buying.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next